5-year Longitudinal Observational Study of Patients Undergoing Therapy for



Reference NCT03661866


Estimated Study Completion Date December 31, 2026


Target PharmaSolutions, Inc.

Brief Summary:

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.


For complete details see link below:




Several statewide locations. Contact below to inquire about participation.

Contact: Laura Dalfonso 9842340268

Email: ldalfonso@targetpharmasolutions.com


Contact: Laura Malahias 9842340268 ext 209

Email: lmalahias@targetpharmasolutions.com


© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579